CLAIMS

1. Use of a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor in manufacture of a medicament for treatment or prevention of constipation;

wherein the DGAT1 inhibitor is trans-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexane acetic acid (pradigastat) or a pharmaceutically acceptable salt or ester thereof; and

wherein the constipation is opioid-induced constipation, chronic idiopathic constipation, or constipation due to pregnancy, medications, or a neurological disorder.

2. The use according to claim 1, wherein the constipation is chronic idiopathic constipation.

3. The use according to claim 1, wherein the constipation is opioid-induced constipation.

4. The use according to any one of claims 1 to 3, wherein the medicament is for treatment or prevention in a human.

5. The use according to claim 1, wherein the neurological disorder is autonomic neuropathy, diabetic-related neuropathy, multiple sclerosis, spinal cord injury, or stroke.

6. Use of a pharmaceutical composition comprising diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor in manufacture of a medicament for treatment or prevention of constipation;

wherein the DGAT1 inhibitor is trans-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexane acetic acid (pradigastat) or a pharmaceutically acceptable salt or ester thereof; and

wherein the constipation is opioid-induced constipation, chronic idiopathic constipation, or constipation due to pregnancy, medications, or a neurological disorder.

7. The use according to claim 6, wherein the constipation is chronic idiopathic constipation.

8. The use according to claim 6, wherein the constipation is opioid-induced constipation.

9. The use according to any one of claims 6 to 8, wherein the medicament is for treatment or prevention in a human.

10. The use according to claim 6, wherein the neurological disorder is autonomic neuropathy, diabetic-related neuropathy, multiple sclerosis, spinal cord injury, or stroke.